Mcl-1 accumulated in CD34 (+) AML cells upon bortezomib treatment and inhibition of Mcl-1 by shRNA significantly improved the sensitivity of CD34(+) AML cells to bortezomib. Here, CD34 is linked to acute myeloid leukemia.